274 related articles for article (PubMed ID: 15885275)
1. Multidisciplinary management of advanced prostate cancer: changing perspectives on referring patients and enhancing collaboration between oncologists and urologists in clinical trials.
Carducci MA; Carroll PR
Urology; 2005 May; 65(5 Suppl):18-22; discussion 22. PubMed ID: 15885275
[TBL] [Abstract][Full Text] [Related]
2. [Interest of the radiotherapy-hormonotherapy association in the treatment of the high-risk prostate cancer].
Bolla M; Fourneret P; Descotes JL
Bull Cancer; 2008 Dec; 95(12):1213-8. PubMed ID: 19091656
[TBL] [Abstract][Full Text] [Related]
3. Androgen-deprivation therapy as primary treatment for localized prostate cancer: data from Cancer of the Prostate Strategic Urologic Research Endeavor (CaPSURE).
Kawakami J; Cowan JE; Elkin EP; Latini DM; DuChane J; Carroll PR;
Cancer; 2006 Apr; 106(8):1708-14. PubMed ID: 16544313
[TBL] [Abstract][Full Text] [Related]
4. Systemic therapeutic strategies for prostate cancer.
Nelson WG
Clin Adv Hematol Oncol; 2005 Aug; 3(8):619-21. PubMed ID: 16167046
[No Abstract] [Full Text] [Related]
5. Pretreatment prostate-specific antigen velocity is associated with development of distant metastases and prostate cancer mortality in men treated with radiotherapy and androgen-deprivation therapy.
Palma D; Tyldesley S; Pickles T;
Cancer; 2008 May; 112(9):1941-8. PubMed ID: 18338814
[TBL] [Abstract][Full Text] [Related]
6. High risk biochemical relapse and the timing of androgen deprivation therapy.
Ryan CJ; Small EJ
J Urol; 2006 Dec; 176(6 Pt 2):S61-5. PubMed ID: 17084171
[TBL] [Abstract][Full Text] [Related]
7. The continued debate: intermittent vs. continuous hormonal ablation for metastatic prostate cancer.
Gleave M; Klotz L; Taneja SS
Urol Oncol; 2009; 27(1):81-6. PubMed ID: 19111804
[TBL] [Abstract][Full Text] [Related]
8. Androgen deprivation therapy does not impact cause-specific or overall survival in high-risk prostate cancer managed with brachytherapy and supplemental external beam.
Merrick GS; Butler WM; Wallner KE; Galbreath RW; Allen ZA; Adamovich E; Lief J
Int J Radiat Oncol Biol Phys; 2007 May; 68(1):34-40. PubMed ID: 17289288
[TBL] [Abstract][Full Text] [Related]
9. Prostate cancer update: 2007.
Lin AM; Small EJ
Curr Opin Oncol; 2008 May; 20(3):294-9. PubMed ID: 18391629
[TBL] [Abstract][Full Text] [Related]
10. Prostate-cancer-specific survival and clinical progression-free survival in men with prostate cancer treated intermittently with testosterone-inactivating pharmaceuticals.
Scholz M; Lam R; Strum S; Jennrich R; Johnson H; Trilling T
Urology; 2007 Sep; 70(3):506-10. PubMed ID: 17905106
[TBL] [Abstract][Full Text] [Related]
11. Cancer-specific mortality after radiation therapy with short-course hormonal therapy or radical prostatectomy in men with localized, intermediate-risk to high-risk prostate cancer.
Tsai HK; Chen MH; McLeod DG; Carroll PR; Richie JP; D'Amico AV
Cancer; 2006 Dec; 107(11):2597-603. PubMed ID: 17039498
[TBL] [Abstract][Full Text] [Related]
12. Prostate specific antigen half-time and prostate specific antigen doubling time as predictors of response to androgen deprivation therapy for metastatic prostate cancer.
Park YH; Hwang IS; Jeong CW; Kim HH; Lee SE; Kwak C
J Urol; 2009 Jun; 181(6):2520-4; discussion 2525. PubMed ID: 19371894
[TBL] [Abstract][Full Text] [Related]
13. Use of prostate-specific antigen in the follow-up of patients with localized prostate cancer: results of a nationwide survey of urologists.
Penson D; Moul J; Gandhi S; Newling D
Urology; 2006 Jul; 68(1):80-4. PubMed ID: 16777198
[TBL] [Abstract][Full Text] [Related]
14. Management of high risk metastatic prostate cancer: the case for novel therapies.
Brand TC; Tolcher AW
J Urol; 2006 Dec; 176(6 Pt 2):S76-80; discussion S81-2. PubMed ID: 17084174
[TBL] [Abstract][Full Text] [Related]
15. Advancing prostate cancer: treatment options for the urologist.
Lowrance WT; Chang SS
Urol Clin North Am; 2006 May; 33(2):211-7, vii. PubMed ID: 16631459
[TBL] [Abstract][Full Text] [Related]
16. Global update on defining and treating high-risk localized prostate cancer with leuprorelin: a USA perspective--identifying men at diagnosis who are at high risk of prostate cancer death after surgery or radiation therapy.
D'Amico A
BJU Int; 2007 Jan; 99 Suppl 1():13-6; discussion 17-8. PubMed ID: 17229162
[TBL] [Abstract][Full Text] [Related]
17. Association of body mass index with response and survival in men with metastatic prostate cancer: Southwest Oncology Group trials 8894 and 9916.
Montgomery RB; Goldman B; Tangen CM; Hussain M; Petrylak DP; Page S; Klein EA; Crawford ED;
J Urol; 2007 Nov; 178(5):1946-51; discussion 1951. PubMed ID: 17868721
[TBL] [Abstract][Full Text] [Related]
18. The impact of prior radical prostatectomy in men with metastatic castration recurrent prostate cancer: a pooled analysis of 9 Cancer and Leukemia Group B Trials.
Halabi S; Vogelzang NJ; Ou SS; Small EJ
J Urol; 2007 Feb; 177(2):531-4. PubMed ID: 17222627
[TBL] [Abstract][Full Text] [Related]
19. Rising prostate-specific antigen after primary prostate cancer therapy.
Ward JF; Moul JW
Nat Clin Pract Urol; 2005 Apr; 2(4):174-82. PubMed ID: 16474760
[TBL] [Abstract][Full Text] [Related]
20. Alternative nonsteroidal antiandrogen therapy for advanced prostate cancer that relapsed after initial maximum androgen blockade.
Suzuki H; Okihara K; Miyake H; Fujisawa M; Miyoshi S; Matsumoto T; Fujii M; Takihana Y; Usui T; Matsuda T; Ozono S; Kumon H; Ichikawa T; Miki T;
J Urol; 2008 Sep; 180(3):921-7. PubMed ID: 18635218
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
